Molecular or behavioral phenotypes relevant to particular aspects of addiction or schizophrenia. Features of CSMD1’s neurobiology make its variants attractive candidates to contribute to individual differences in vulnerability to addiction and in mnemonic processes. The CSMD1 gene encodes a single transmembrane domain protein likely to alter the development and maintenance of connections between expressing neurons. Abundant CSMD1 immunoreactivity is found at the growth cones of cultured neurons [26]. Ventral midbrain neurons implicated in reward, likely to be dopaminergic, prominently express CSMD1 mRNA, as do hippocampal neurons implicated in mnemonic processes (http://mouse.brain-map.org/experiment/ivt?id= 69608130 popup = true). Results from studies of csmd1 knockouts on mixed genetic backgrounds (see below) also support interesting phenotypes [21,27]. These neurobiologic, genetic and genomic data nominate CSMD1 as a candidate for studies that seek: a) influences of common human purchase ZM241385 allelic variation on CSMD1 expression, b) influences of variation in CSMD1 expression on responses to rewarding addictive substances in mouse models, c) influences of variation in CSMD1 expression on cognitive phenotypes that may model features relevant to schizophrenia and d) comparisons with other physiological and behavioral differences in mice with altered csmd1 expression. We now report studies of CSMD1 expression in human postmortem cerebral cortical samples that identify nominally-significant associations between levels of CSMD1 expression and CSMD1 genomic markers, including those that lie near the schizophrenia-associated SNP rs10503253, though these associations do not survive conservative Bonferroni corrections. We describe our initial data from the csmd1 knockouts on mixed genetic backgrounds and report the variability that differences in genetic background among these mice appears to provide. We then describe more extensive results from “csmd1” knockout mice backcrossed onto a C57 background for 5 generations. We study results of tests that include cocaine conditioned placePLOS ONE | DOI:10.1371/journal.pone.0120908 July 14,2 /CSMD1 Variants and Addictionpreference (CPP), one of the most commonly used and heavily validated mouse tests for drug reward/reinforcement [28]. We demonstrate that mice with altered CSMD1 expression display overall differences in cocaine CPP, although their locomotion is influenced by modest to moderate doses of cocaine in ways similar to those of wildtype mice. There is modestly increased locomotion in homozygous knockouts. We identify order PXD101 alterations in Morris water maze testing in homozygous backcrossed csmd1 knockouts, and discuss the potential implications of these data for the CSMD1 associations with cognitive differences in schizophrenia, in normal populations, and for our CPP data from heterozygous and homozygous mice. We note ways in which these data enhance our confidence that CSMD1 variation and thus the neuronal properties and connections that CSMD1 modulates play roles in addiction phenotypes and in cognition-related phenotypes that are of likely relevance for schizophrenia.Materials and Methods Common human allelic CSMD1 sequence variation was soughtCommon human allelic CSMD1 sequence variation was sought by searches of dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) and the Toronto database for structural/copy number variation (http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg18). Genetic cis influences on levels of.Molecular or behavioral phenotypes relevant to particular aspects of addiction or schizophrenia. Features of CSMD1’s neurobiology make its variants attractive candidates to contribute to individual differences in vulnerability to addiction and in mnemonic processes. The CSMD1 gene encodes a single transmembrane domain protein likely to alter the development and maintenance of connections between expressing neurons. Abundant CSMD1 immunoreactivity is found at the growth cones of cultured neurons [26]. Ventral midbrain neurons implicated in reward, likely to be dopaminergic, prominently express CSMD1 mRNA, as do hippocampal neurons implicated in mnemonic processes (http://mouse.brain-map.org/experiment/ivt?id= 69608130 popup = true). Results from studies of csmd1 knockouts on mixed genetic backgrounds (see below) also support interesting phenotypes [21,27]. These neurobiologic, genetic and genomic data nominate CSMD1 as a candidate for studies that seek: a) influences of common human allelic variation on CSMD1 expression, b) influences of variation in CSMD1 expression on responses to rewarding addictive substances in mouse models, c) influences of variation in CSMD1 expression on cognitive phenotypes that may model features relevant to schizophrenia and d) comparisons with other physiological and behavioral differences in mice with altered csmd1 expression. We now report studies of CSMD1 expression in human postmortem cerebral cortical samples that identify nominally-significant associations between levels of CSMD1 expression and CSMD1 genomic markers, including those that lie near the schizophrenia-associated SNP rs10503253, though these associations do not survive conservative Bonferroni corrections. We describe our initial data from the csmd1 knockouts on mixed genetic backgrounds and report the variability that differences in genetic background among these mice appears to provide. We then describe more extensive results from “csmd1” knockout mice backcrossed onto a C57 background for 5 generations. We study results of tests that include cocaine conditioned placePLOS ONE | DOI:10.1371/journal.pone.0120908 July 14,2 /CSMD1 Variants and Addictionpreference (CPP), one of the most commonly used and heavily validated mouse tests for drug reward/reinforcement [28]. We demonstrate that mice with altered CSMD1 expression display overall differences in cocaine CPP, although their locomotion is influenced by modest to moderate doses of cocaine in ways similar to those of wildtype mice. There is modestly increased locomotion in homozygous knockouts. We identify alterations in Morris water maze testing in homozygous backcrossed csmd1 knockouts, and discuss the potential implications of these data for the CSMD1 associations with cognitive differences in schizophrenia, in normal populations, and for our CPP data from heterozygous and homozygous mice. We note ways in which these data enhance our confidence that CSMD1 variation and thus the neuronal properties and connections that CSMD1 modulates play roles in addiction phenotypes and in cognition-related phenotypes that are of likely relevance for schizophrenia.Materials and Methods Common human allelic CSMD1 sequence variation was soughtCommon human allelic CSMD1 sequence variation was sought by searches of dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) and the Toronto database for structural/copy number variation (http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg18). Genetic cis influences on levels of.
Related Posts
Sidue peptide, ACTH (eight). ACTH is derived from a larger precursor protein, pro-opiomelanocortin (POMC), by
Sidue peptide, ACTH (eight). ACTH is derived from a larger precursor protein, pro-opiomelanocortin (POMC), by the action of a particular pro-hormone convertase enzyme (PC1 or PCSK1) (9). In other tissues as an example, the hypothalamus this precursor is processed differently to make -MSH as opposed to ACTH (10). ACTH is synthesized and secreted by the […]
He moderately stained neurons of the medial and lateral MedChemExpress Caerulein habenular nuclei(Fig 1J, MHb,
He moderately stained neurons of the medial and lateral MedChemExpress Caerulein habenular nuclei(Fig 1J, MHb, LHb) within the epithalamus. Much more strongly stained neurons have been discovered within the mediodorsal, lateral dorsal, and ventral lateral thalamic nuclei (Fig 1J, MD, LD, VL) too because the reuniens thalamic nucleus(Fig 1J, Re). Scattered lightly to moderately stained […]
He animal experiments were approved (License Number 129/2009) by the Ethics Committee
He animal experiments were approved (License Number 129/2009) by the Ethics Committee 15900046 of the Veterinary Office of the Kanton Zurich ?and were conducted in accordance with the guidelines of the “Schweizer Bundesamt fur Veterinarwesen”. On day 0 of the ??experiments, 26105 of 143-B cells (engineered as described) in 10 ml of PBS/0.05 EDTA containing […]